# Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

> **NCT03493945** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 59 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- Prostate Cancer
- Prostate Neoplasm
- Advanced Solid Tumor
- Solid Tumor
- Non-metastatic Castration-resistant Prostate Cancer

## Interventions

- **BIOLOGICAL:** M7824
- **DRUG:** N-803
- **BIOLOGICAL:** MVA-BN-Brachyury
- **BIOLOGICAL:** FPV-Brachyury
- **DRUG:** Epacadostat
- **DRUG:** Acetaminophen
- **DRUG:** Ibuprofen
- **DRUG:** Naproxen
- **OTHER:** Benadryl
- **DIAGNOSTIC_TEST:** EKG
- **DIAGNOSTIC_TEST:** Bone scan
- **DIAGNOSTIC_TEST:** CT chest, abdomen and pelvis
- **DIAGNOSTIC_TEST:** MRI

## Key facts

- **NCT ID:** NCT03493945
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2024-10-08
- **Final completion:** 2024-10-08
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03493945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03493945, "Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03493945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*